Trial Profile
A 26-Week Extension Study of the Safety and Clinical Effects of EVP-6124 in Subjects With Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 07 Apr 2022
Price :
$35
*
At a glance
- Drugs Encenicline (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors FORUM Pharmaceuticals
- 06 Apr 2022 This trial has been completed in Netherland (Global end date: 23/12/2015), according to European Clinical Trials Database record.
- 02 May 2016 Status changed from suspended to discontinued.
- 14 Sep 2015 Status changed from recruiting to suspended, as per Forum Pharmaceuticals media release.